BRIEF-Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting Potential Of Nicotinamide Riboside (NR) For Werner Syndrome, A Rare Genetic Disorder

Reuters
09 Jun
BRIEF-<a href="https://laohu8.com/S/NAGE">Niagen Bioscience</a> Announces First-Ever Peer-Reviewed Study Highlighting Potential Of Nicotinamide Riboside (NR) For Werner Syndrome, A Rare Genetic Disorder

June 9 (Reuters) - Niagen Bioscience Inc NAGE.O:

  • NIAGEN BIOSCIENCE ANNOUNCES FIRST-EVER PEER-REVIEWED STUDY HIGHLIGHTING THE POTENTIAL OF NICOTINAMIDE RIBOSIDE (NR) FOR WERNER SYNDROME, A RARE GENETIC DISORDER

Source text: ID:nBw188W8Ca

Further company coverage: NAGE.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10